A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 417 participants.
Also called NCT05171075
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 417 participants
- Registry
-
NCT05171075 -
2021-003085-12
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Austria, Canada, China, Czechia, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05171075. Randomized; single masking; primary purpose treatment. Start 2022-09-27 (actual); primary completion 2026-04-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
- Acronym
- MAGNOLIA
- Condition
- Venous Thromboembolism
- Condition
- Deep Venous Thrombosis
- Condition
- Pulmonary Embolism
- Intervention (Biological)
- Abelacimab
- Intervention (Drug)
- Dalteparin
- Lead sponsor
- Anthos Therapeutics, Inc.
- Collaborator
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05171075- Content hash
7e6a81c29b4855434772cf54f08aaba626d040d6d2b7ca481ccd6e5713c35fc8